The healthcare industry was one of the few growth areas during the recession of 2008 and 2009, and in the United States was front and centre in the news as Pres. Obama’s promised health care reform took a considerable amount of time in Congress. Indeed, the healthcare business was a pivotal part of Obama’s campaign and he wasted no time in prompting both houses of Congress to consider change. Could it be that we are poised for a momentous change in this industry, one which will reach every person in the country, ranging from individuals through insurance companies, hospitals to pharmaceutical companies? In these tumultuous times, the role of healthcare and pharmaceutical consulting organisations will be pivotal and all the skills possessed by these companies will be necessary as changes are processed and results analysed.

Healthcare will be a growing industry for the foreseeable future, especially as the generation known as “baby boomers” comes of a certain age, representing a strain on the overall health care system. A pharmaceutical company will need to be on its toes, innovative and ready to provide additional products and services. The marketplace is sure to get more and more competitive.

A spotlight will always be trained on costs and the role of the insurance company as intermediary between both ends of the spectrum. Healthcare professionals will be under more and more pressure to correctly advise their patients, especially in the light of new legislation and new rules. In short, a period of uncertainty can be expected to add even more pressures to an already pressure packed environment.

In the future, pharmaceutical consultants, already in high demand, will be even more valuable as the role of pharma consulting extends to decipher these new rules and implications. Training of the company’s workforce is best engaged with the help of consultants, who provide an extra layer of expertise, experience and training themselves. Executives from the parent company must spend as much time as possible dealing with the principal concerns associated with production and regulation. They should devote valuable time to staff administration, maintenance and training. The pharmaceutical consulting firm is ready and able to take on this element of the organisation and to ensure that sales executives implement correctly and bring as valuable a return as possible to the company’s bottom line.

The healthcare business is one of our most dynamic industries and pharmaceutical and healthcare consulting is a critical internal component. Not all organisations interested in the development of a pharmaceutical company can be classified as “friendly” and this puts significant pressures on the company. A pharmaceutical consulting firm is best positioned to advise the company’s executives, by interpreting each position and working out how to approach and handle each party from a position of strength. Make no mistake, there are challenging and risky times ahead, yet these times could also be potentially lucrative and the consultant can be an additional pair of ears and eyes, together with a valued resource. The company is advised to consider a long-term engagement with the pharmaceutical and healthcare consulting firm accordingly.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.